Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor therapy is an effective low-density lipoprotein cholesterol (LDL-C) lowering option for patients with the highest risk of cardiovascular disease (CVD) events and high LDL-C despite the use of statin therapy, according to a recent review. Clinical trials include were from January 2012 to March 2018. Researchers found:
- All trials evaluating evolocumab and alirocumab demonstrated significant LDL-C lowering vs comparators.
- 2 trials revealed a decrease in the major adverse cardiovascular events (MACE) end point with PCSK9 inhibitor use.
- No significant safety concerns apart from injection site reactions were noted.
Patel RS, Scopelliti EM, Olugbile O. The role of PCSK9 inhibitors in the treatment of hypercholesterolemia. [Published online ahead of print April 1, 2018]. Ann Pharmacother. doi:10.1177/1060028018771670.